Aurora Rebrands German EU-GMP Production Hub, Doubles Flower Output

EDMONTON – Aurora Cannabis Inc. announced the completion of a major expansion at its EU-GMP manufacturing facility in Leuna, Germany. The company is projecting annual flower output at the site to more than double as a result of the investment. To commemorate the site’s transformation, the facility has been renamed Aurora Horizon, a name selected by the local team, reflective of their pride and optimism for the facility’s future.

The expansion incorporates cultivation and post-harvest practices from Aurora’s Canadian operations, including lighting, irrigation, harvesting, and post-harvest processes. The facility has also adopted genetics from Aurora Coast, the company’s R&D operation in British Columbia.

Germany’s State Office for Social Affairs, Youth and Health of Saxony-Anhalt extended an EU-GMP manufacturing license to the newly built sections of the Leuna site. That clearance allows Aurora Horizon to distribute compliant product into Germany and across broader European medical markets. The company added that the expanded facility is expected to support additional job creation in Saxony-Anhalt, though no employment figures were provided.

Aurora confirmed the investment was multimillion-dollar but did not disclose the facility’s previous production volume, its new projected annual output, or the exact cost of the expansion, leaving independent verification of the output projection unavailable.

The announcement arrives against a backdrop of surging demand. Germany has become Europe’s largest regulated Cannabis market, with imports rising from 8,143 kilograms in Q1 2024 to 50,539 kilograms in Q1 2026 – a more than sixfold increase following the April 2024 reform that removed Cannabis from Germany’s narcotics register. The German medical market was valued at approximately €670 million in 2025, with projections pointing toward €1.3 billion by 2029.

Yet the country’s supply base remains thin. Domestic facilities cover an estimated less than 3% of national demand, and only three in-country licensed producers operate in Germany; two of them subsidiaries of Canadian companies. Aurora holds one of those three licenses, alongside Aphria/Tilray’s German operation and Demecan.

That structural reality is the most salient aspect of the story. A licensed domestic producer operating under EU-GMP certification occupies a different commercial position than an importer:

• closer to the prescriber network,
• less exposed to cross-border logistics, and
• more credible to institutional buyers who weigh local provenance.

The German government is also reported to be considering tighter controls on medical prescribing to curb potential misuse, a regulatory tightening that will likely favor established, compliant producers over the market’s more opportunistic edges. Aurora Horizon represents Aurora’s clearest statement yet that it intends to compete in Europe by building genuine manufacturing depth on German soil. Not simply by shipping volume into it.